BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: GlobeNewswire
Further expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates BioNTech’s global expansion by creating a U.S. hub for research and clinical development Creates long-term value for BioNTech and Neon shareholders by combining capabilities, IP and synergistic pipeline programs Transaction expected to close in the second quarter of 2020 MAINZ, Germany and CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million. Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology company focuse
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $130.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $125.00 price target on the stock, up previously from $110.00.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.MarketBeat
- BioNTech to Acquire Biotheus to Boost Oncology StrategyGlobeNewswire
BNTX
Earnings
- 11/4/24 - Beat
BNTX
Sec Filings
- 11/15/24 - Form 144
- 11/14/24 - Form 6-K
- 11/13/24 - Form 6-K
- BNTX's page on the SEC website